《亚太地区慢性乙型肝炎管理共识:2012年更新版》解读:治疗策略、耐药处理和无创肝纤维化评估

樊蓉; 梁携儿; 孙剑; 侯金林

《亚太地区慢性乙型肝炎管理共识:2012年更新版》解读:治疗策略、耐药处理和无创肝纤维化评估

南方医科大学南方医院肝病中心和感染内科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 197
- HTML全文浏览量: 25
- PDF下载量: 405
- 被引次数: 0
出版历程
- 出版日期: 2012-07-20

Explanation of the “Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update”: Treatment strategy, resistance management and non-invasive evalution of liver fibrosis

Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University

摘要

摘要: <正>2012年2月18日,亚太肝脏研究学会(APASL)在台湾召开的亚太肝脏病年会上发布了备受关注的《亚太地区慢性乙型肝炎管理共识:2012年更新版》(以下简称2012年共识)[1],这是自2000年发布第一版共识以来,历经2003、2005和2008年3次更新和修订,时隔4年第5次发布修订的共识意见。2012年共识紧密结合亚太地区慢性乙型肝炎(CHB)的流行病学特点及医疗现状,总结
- 肝炎,乙型,慢性 /
- 指南
- hepatitis B /
- chronic

HTML全文

参考文献(14)

[1]Liaw YF, Kao JH, Piratvisuth T, et al.Asian-Pacific Con-sensus statement on the management of chronic hepatitis B:A 2012 update[J].Hepatol Int, 2012, 6 (3) :531-561.

[2]European Association For The Study Of The Liver.EASL Clin-ical Practice Guidelines:Management of chronic hepatitis B[J].J Hepatol, 2009, 50 (2) :227-242.

[3] Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009[J]. Hepatology, 2009, 50 (3) : 661-662.

[4]Sung JJY, Tsoi KKF, Wong VWS, et al.Meta-analysis:treat-ment of hepatitis B infection reduces risk of hepatocellular carcino-ma[J].Aliment Pharmacol Ther, 2008, 28 (9) :1067-1077.

[5]Chu CM, Liaw YF.Chronic hepatitis B virus infection ac-quired in childhood:special emphasis on prognostic andtherapeutic implication of delayed HBeAg seroconversion[J].J Viral Hepat, 2007, 14 (3) :147-152.

[6] Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection[J]. J Hepatol, 2007, 47 (6) : 760-767.

[7]Liaw YF, Jia JD, Chan HLY, et al.Shorter durations and lowerdoses of peginterferon alfa-2a are associated with inferior hepati-tis B e antigen seroconversion rates in hepatitis B virus genotypesB or C[J].Hepatology, 2011, 54 (5) :1591-1599.

[8]Sonneveld MJ, Wong VWS, Woltman AM, et al.Polymor-phisms near IL28B and serologic response to peginterferon inHBeAg-positive patients with chronic hepatitis B[J].Gas-troenterology, 2012, 142 (3) :513-520.e1.

[9]Buster EHCJ, Hansen BE, Lau GKK, et al.Factors that pre-dict response of patients with hepatitis B e antigen–positivechronic hepatitis B to peginterferon-alfa[J].Gastroenterol-ogy, 2009, 137 (6) :2002-2009.

[10]Degos F, Perez P, Roche B, et al.Diagnostic accuracy of Fi-broScan and comparison to liver fibrosis biomarkers in chronicviral hepatitis:a multicenter prospective study (the FIBROS-TIC study) [J].J Hepatol, 2010, 53 (6) :1013-1021.

[11] Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B[J]. Liver Int, 2009, 29 (2) : 242-247.

[12]Chan HL, Wong GL, Choi PC, et al.Alanine aminotrans-ferase-based algorithms of liver stiffness measurement bytransient elastography (Fibroscan) for liver fibrosis in chron-ic hepatitis B.[J].J Viral Hepat, 2009, 16 (1) :36-44.

[13] Sporea I, Sirli RL, Deleanu A, et al. Acoustic radiation force impulse elastography as compared to transient elastography and liver biopsy in patients with chronic hepatopathies[J]. Ultraschall Med, 2011, 32 (Suppl 1) : S46-S52.

[14]Wong GL, Wong VW, Choi PC, et al.Development of a non-invasive algorithm with transient elastography (Fibroscan (R) ) and serum test formula for advanced liver fibrosis inchronic hepatitis B[J].Aliment Pharmacol Ther, 2010, 31 (10) :1095-1103.

施引文献

资源附件(0)

访问统计